TABLE 10. Writing Group Disclosures

Writing Group Member NameEmploymentResearch GrantSpeakers Bureau/HonorariaStock OwnershipConsultant/Advisory BoardOther
This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit.
Larry B. GoldsteinDuke Center for Cerebrovascular Disease, Duke University Medical Center; Durham Veterans Administration Medical CenterGrants: NIH, Veterans Administration, CDC/University of North Carolina–Chapel Hill, Pfizer/Parke-Davis (SPARCL Steering Committee) Clinical trial site: Boehringer Ingelheim, AGA CorpSpeaking honoraria: Bayer, Pfizer/Parke Davis Speakers bureau: NoneNoneAstraZeneca, Bristol-Myers Squibb/Sanofi, CuraGen Corp, DPharm, GlaxoSmithKline, Johnson&Johnson, Merck Research Laboratories, Pfizer/ Parke DavisNone
Robert AdamsMedical College of GeorgiaNoneBoehringer Ingelheim, BMS, Wyeth, Sanofi-Synthelabo, NovartisNoneBoehringer Ingelheim, BMS, Sanofi-Synthelabo, WyethAcuson, ATL, BMS, Boehringer Ingelheim, Nicolet
Mark J. AlbertsNorthwestern University Medical SchoolNoneNoneAstraZeneca, Bristol-Myers Squibb, SanofiNoneNone
Lawrence J. AppelJohns HopkinsNoneNoneNoneNoneNone
Lawrence M. BrassYale UniversityBristol-Myers Squibb, Sanofi/SynthelaboBristol-Myers Squibb, Sanofi/Synthelabo, Solvay Pharmaceuticals, WyethNoneAstraZeneca, Bristol-Myers Squibb, Merck, ONO Pharmaceuticals, Sanofi/Synthelabo, Solvay Pharmaceuticals, WyethNone
Cheryl D. BushnellDuke Center for Cerebrovascular Disease, Duke University Medical CenterNoneNoneNoneNoneNone
Antonio CulebrasUpstate Medical UniversityNoneBoehringer IngelheimNoneNoneNone
Thomas J. DeGrabaNational Naval Medical CenterUniformed Services University of Health Sciences.NoneNoneNoneNone
Philip B. GorelickUniversity of Illinois at ChicagoNoneBayer, Bristol-Meyers Squibb–Sanofi, Boerhinger-Ingelheim, Merck, Pfizer, WyethNoneBayer, Bristol-Meyers Squibb–Sanofi, Boerhinger-Ingelheim, Merck, Pfizer, WyethNone
John R. GuytonDuke University Medical CenterAstraZeneca, Bayer, GlaxoSmithKline, Kos, Merck, Pfizer, Schering PloughAstraZeneca, GlaxoSmithKline, Kos, Merck, Pfizer, Sankyo PharmaNoneAstraZeneca, Kos, Merck/Schering, Sankyo Pharma, TakedaNone
Robert G. HartUniversity of Texas Health Science CenterNoneNoneNoneNoneData safety monitoring boards of clinical trials sponsored by Pfizer (SPARCL), AstraZeneca (SPORTIF III and V), and Sanofi (CHARISMA)
George HowardUniversity of Alabama at BirminghamNoneNoneNoneNoneNone
Margaret Kelly-HayesBoston University School of MedicineNoneNoneNoneNoneNone
J. V. (Ian) NixonMedical College of VirginiaNoneNoneNoneNoneNone
Ralph L. SaccoColumbia UniversityNoneBoehringer Ingelheim (Pharm), Sanofi (Pharm)/Bristol-Myers/SquibbNoneBoehringer Ingelheim (Pharm), GlaxoSmithKline (Pharm)None